From orbit to cortex: recognising teprotumumab-induced encephalopathy.

Authors

• Alan R Spicer, Lehigh Valley Health NetworkFollow
• Zuhair Siddiqui DO, Lehigh Valley Health NetworkFollow
• Ping-Hao Yang MD, Lehigh Valley Health NetworkFollow
• Ramya Punati MD, Lehigh Valley Health NetworkFollow
• Connie G. Tang MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

5-8-2026

Abstract

Autoimmune-related adverse effects may occur from monoclonal antibody medications though autoimmune encephalopathy is not a commonly reported reaction. Inhibiting the insulin-like growth factor 1 pathway has been shown to cause neurocognitive side effects. We report a case of a man in his early 60s who presented with neuropsychiatric changes after beginning teprotumumab for thyroid eye disease. He was diagnosed with teprotumumab-induced encephalopathy and ultimately treated with plasma exchange.

Volume

19

Issue

5

ISSN

1757-790X

Published In/Presented At

Spicer, A., Siddiqui, Z., Yang, P. H., Punati, R., & Tang, C. (2026). From orbit to cortex: recognising teprotumumab-induced encephalopathy. BMJ case reports, 19(5), e271752. https://doi.org/10.1136/bcr-2025-271752

Disciplines

Medicine and Health Sciences

PubMedID

42103337

Department(s)

Department of Medicine, Department of Surgery, USF-LVHN SELECT Program, USF-LVHN SELECT Program Students, USF-LVHN SELECT Program Faculty, Fellows and Residents

Document Type

Article